- Home
- KNOP vs LRMR Comparison
KNOP vs LRMR Comparison
Compare KNOP & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- LRMR
- Stock Information
- Founded
- KNOP 2013
- LRMR N/A
- Country
- KNOP United Kingdom
- LRMR United States
- Employees
- KNOP N/A
- LRMR N/A
- Industry
- KNOP Marine Transportation
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- LRMR Health Care
- Exchange
- KNOP Nasdaq
- LRMR Nasdaq
- Market Cap
- KNOP 199.5M
- LRMR 183.8M
- IPO Year
- KNOP 2013
- LRMR N/A
- Fundamental
- Price
- KNOP $7.62
- LRMR $2.00
- Analyst Decision
- KNOP
- LRMR Strong Buy
- Analyst Count
- KNOP 0
- LRMR 10
- Target Price
- KNOP N/A
- LRMR $19.60
- AVG Volume (30 Days)
- KNOP 91.4K
- LRMR 906.5K
- Earning Date
- KNOP 03-19-2025
- LRMR 05-08-2025
- Dividend Yield
- KNOP 1.36%
- LRMR N/A
- EPS Growth
- KNOP N/A
- LRMR N/A
- EPS
- KNOP 0.18
- LRMR N/A
- Revenue
- KNOP $312,629,000.00
- LRMR N/A
- Revenue This Year
- KNOP $1.40
- LRMR N/A
- Revenue Next Year
- KNOP $2.53
- LRMR N/A
- P/E Ratio
- KNOP $37.75
- LRMR N/A
- Revenue Growth
- KNOP 8.60
- LRMR N/A
- 52 Week Low
- KNOP $4.94
- LRMR $1.96
- 52 Week High
- KNOP $9.11
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- KNOP 81.62
- LRMR 29.98
- Support Level
- KNOP $6.53
- LRMR $2.19
- Resistance Level
- KNOP $6.84
- LRMR $2.44
- Average True Range (ATR)
- KNOP 0.25
- LRMR 0.18
- MACD
- KNOP 0.17
- LRMR -0.01
- Stochastic Oscillator
- KNOP 95.77
- LRMR 4.81
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.